NICE recommends tirzepatide for type 2 diabetes in final draft guidance

Following additional analyses and modelling of clinical and cost effectiveness, the National Institute for Health and Care Excellence has recommended tirzepatide for type 2 diabetes mellitus.
person injecting mounjaro
Evidence from clinical trials showed that weekly injection of tirzepatide resulted in significant reductions in blood sugar levels and body weight

Shutterstock.com

The National Institute for Health and Care Excellence (NICE) has recommended tirzepatide (Mounjaro; Eli Lilly) for the treatment of type 2 diabetes mellitus (T2DM), reversing its initial decision against use of the drug in June 2023.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated